; (ii) monitoring of tumor response to treatment, including recurrence and progression; and (iii) accurate assessment and surveillance of indolent disease to reduce unnecessary biopsies and treatment; (B) provide information and coordination of prostate cancer research and services across all Federal agencies; (C) review diagnostic tools and their overall effectiveness at screening, detecting, assessing, and monitoring of prostate cancer; (D) evaluate all programs in prostate cancer that are in existence on the date of enactment of this Act, including Federal budget requests and approvals and public-private partnerships; (E) submit an annual report to the Secretary and Congress on the creation and implementation of the national strategic plan under subparagraph (A)